Barclays' Head of US Biopharma Equity Research Emily Field Told CNBC Monday August 24, 2026 That the Biotech Mergers and Acquisitions (M&A) Freeze Is Over, With Capital Markets Reopening, Large-Cap Pharma Buyers Committing to More Deals, and Fresh Oncology Data Extending the Sector's Value Proposition Beyond Weight-Loss Drugs; The Commentary Follows a Rapid Acceleration of Biotech M&A Activity Through August Including Samsung Biologics' Pending $1.8 Billion PolyPeptide Group Acquisition, BioMarin's Alesta Therapeutics Acquisition, Tolerance Bio's $260 Million NT-I7 License From NeoImmuneTech, LEO Pharma's Dersimelagon Acquisition From Mitsubishi Tanabe, and Hanmi Pharm's $2.3 Billion HM17321 Licensing to Genentech Announced the Same Monday
Barclays' Head of US Biopharma Equity Research Emily Field told CNBC Monday August 24, 2026 that the biotech mergers and acquisitions (M&A) freeze is over. Key drivers cited: capital markets reopening (drug startup IPOs have raised roughly $6 billion year-to-date, more than the combined total of the prior four years by this point), large-cap pharma buyers committing to more deals following a multi-year period of caution, and fresh oncology data extending the sector's value proposition beyond the weight-loss drug narrative that dominated 2024-2025. The commentary follows a rapid acceleration of biotech M&A activity through August: Samsung Biologics' pending $1.8 billion PolyPeptide Group AG all-cash tender offer (formal prospectus expected end of August), BioMarin Pharmaceutical's Alesta Therapeutics acquisition for ALE1 program (August 21), Tolerance Bio's $260 million exclusive license from NeoImmuneTech for NT-I7 (efineptakin alfa, long-acting IL-7 fusion protein, August 20), LEO Pharma's dersimelagon (MC1R agonist) acquisition from Mitsubishi Tanabe (August 18), and Hanmi Pharm's up-to-$2.3 billion HM17321 UCN2 licensing to Genentech announced the same Monday. The pattern suggests the M&A environment is now supportive for both mid-cap platform buyers (Samsung Biologics, LEO Pharma, BioMarin) and mega-cap oncology and metabolic-disease buyers (Roche/Genentech, Bristol Myers Squibb, Merck, Eli Lilly) actively pursuing deals. Field's commentary also notes that oncology data (particularly the Merck-Moderna intismeran Phase 3 melanoma win and Gilead Trodelvy+Keytruda EU authorization from the same week) has substantially reset investor expectations about the sector beyond obesity.